{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:30:35Z","timestamp":1786527035547,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,12]]},"DOI":"10.7759\/cureus.114395","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:42:36Z","timestamp":1786524156000},"source":"Crossref","is-referenced-by-count":0,"title":["Psoriasis Treatment Success With Bimekizumab: Two Hard-to-Treat Cases"],"prefix":"10.7759","author":[{"given":"Ahmed","family":"Ameen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal S","year":"2021","unstructured":"Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2021, 84:46-52. 10.1016\/j.jaad.2020.04.139","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi R","year":"2020","unstructured":"Parisi R, Iskandar IY, Kontopantelis E, Augustin M, Griffiths CE, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020, 369:m1590. 10.1136\/bmj.m1590","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13407","article-title":"Psoriasis: a bibliometric analysis in the Arab World (2004-2019)","volume":"62","author":"Daou L","year":"2021","unstructured":"Daou L, El Hage S, Wakim E, Safi S, Salameh P. Psoriasis: a bibliometric analysis in the Arab World (2004-2019). Australas J Dermatol. 2021, 62:e19-23. 10.1111\/ajd.13407","journal-title":"Australas J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JDN.0000000000000418","article-title":"Manifestations and management of difficult-to-treat psoriasis","volume":"10","author":"Aldredge LM","year":"2018","unstructured":"Aldredge LM, Higham RC. Manifestations and management of difficult-to-treat psoriasis. J Dermatol Nurses Assoc. 2018, 10:189-97. 10.1097\/JDN.0000000000000418","journal-title":"J Dermatol Nurses Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000504841","article-title":"Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry","volume":"237","author":"Callis Duffin K","year":"2021","unstructured":"Callis Duffin K, Mason MA, Gordon K, et al.. Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry. Dermatology. 2021, 237:46-55. 10.1159\/000504841","journal-title":"Dermatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1448788","article-title":"Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas","volume":"19","author":"Kivelevitch D","year":"2018","unstructured":"Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother. 2018, 19:561-75. 10.1080\/14656566.2018.1448788","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola JF","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018, 31:e12589. 10.1111\/dth.12589","journal-title":"Dermatol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6498","article-title":"Treatment of scalp psoriasis","volume":"21","author":"Ghafoor R","year":"2022","unstructured":"Ghafoor R, Patil A, Yamauchi P, Weinberg J, Kircik L, Grabbe S, Goldust M. Treatment of scalp psoriasis. J Drugs Dermatol. 2022, 21:833-7. 10.36849\/JDD.6498","journal-title":"J Drugs Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management","volume":"11","author":"Mosca M","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021, 11:769-97. 10.1007\/s13555-021-00521-z","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2215987","article-title":"Updates in treatment and impact of nail psoriasis","volume":"19","author":"Iorizzo M","year":"2023","unstructured":"Iorizzo M, Tosti A. Updates in treatment and impact of nail psoriasis. Expert Rev Clin Immunol. 2023, 19:1091-100. 10.1080\/1744666X.2023.2215987","journal-title":"Expert Rev Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201471","article-title":"Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs","volume":"48","author":"Kaeley GS","year":"2021","unstructured":"Kaeley GS, Eder L, Aydin SZ, Rich P, Bakewell CJ. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021, 48:1208-20. 10.3899\/jrheum.201471","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2000.00663.x","article-title":"Management of nail psoriasis","volume":"25","author":"de Berker D","year":"2000","unstructured":"de Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000, 25:357-62. 10.1046\/j.1365-2230.2000.00663.x","journal-title":"Clin Exp Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy","volume":"57","author":"Jiaravuthisan MM","year":"2007","unstructured":"Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007, 57:1-27. 10.1016\/j.jaad.2005.07.073","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis","volume":"59","author":"Simopoulou T","year":"2023","unstructured":"Simopoulou T, Tsiogkas SG, Zafiriou E, Bogdanos DP. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs Today (Barc). 2023, 59:135-67. 10.1358\/dot.2023.59.3.3419557","journal-title":"Drugs Today (Barc)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball AB","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al.. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024, 403:2504-19. 10.1016\/S0140-6736(24)00101-6","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde D","year":"2023","unstructured":"van der Heijde D, Deodhar A, Baraliakos X, et al.. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023, 82:515-26. 10.1136\/ard-2022-223595","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon KB","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al.. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021, 397:475-86. 10.1016\/S0140-6736(21)00126-4","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren RB","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al.. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021, 385:130-41. 10.1056\/NEJMoa2102388","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich K","year":"2021","unstructured":"Reich K, Papp KA, BlauveltA, et al.. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021, 397:487-98. 10.1016\/S0140-6736(21)00125-2","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.094","article-title":"Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: results from the BE RADIANT phase 3b trial","volume":"89","author":"Eyerich K","year":"2023","unstructured":"Eyerich K, Gottlieb AB, Piaserico S, et al.. Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: results from the BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023, 89:22.","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.6.3400572","article-title":"Bimekizumab for psoriasis","volume":"58","author":"Rodrigues MA","year":"2022","unstructured":"Rodrigues MA, Freitas E, Torres T. Bimekizumab for psoriasis. Drugs Today (Barc). 2022, 58:273-82. 10.1358\/dot.2022.58.6.3400572","journal-title":"Drugs Today (Barc)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2218086","article-title":"Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation","volume":"22","author":"Ruggiero A","year":"2023","unstructured":"Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023, 22:355-62. 10.1080\/14740338.2023.2218086","journal-title":"Expert Opin Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations","volume":"34","author":"Nast A","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al.. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020, 34:2461-98. 10.1111\/jdv.16915","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/02666211213145047","article-title":"Systemic treatments for adult patients with moderate-to-severe psoriasis: consensus statements for the United Arab Emirates","volume":"3","author":"Hammadi AA","year":"2022","unstructured":"Hammadi AA, Murrawi AM, Ali RH, et al.. Systemic treatments for adult patients with moderate-to-severe psoriasis: consensus statements for the United Arab Emirates. New Emir Med J. 2022, 3:18. 10.2174\/02666211213145047","journal-title":"New Emir Med J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_420_23","article-title":"Disease assessment in psoriasis","volume":"68","author":"Manchanda Y","year":"2023","unstructured":"Manchanda Y, De A, Das S, Chakraborty D. Disease assessment in psoriasis. Indian J Dermatol. 2023, 68:278-81. 10.4103\/ijd.ijd_420_23","journal-title":"Indian J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19:210-6. 10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clin Exp Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore F","year":"2019","unstructured":"Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019, 33:464-83. 10.1111\/jdv.15340","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","article-title":"Cosentyx (secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis","volume":"9","author":"Fala L","year":"2016","unstructured":"Fala L. Cosentyx (secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am Health Drug Benefits. 2016, 9:60-3.","journal-title":"Am Health Drug Benefits"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter A","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al.. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019, 80:1029-72. 10.1016\/j.jaad.2018.11.057","journal-title":"J Am Acad Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01099-y","article-title":"The efficacy and safety of bimekizumab for plaque psoriasis: an expert consensus panel","volume":"14","author":"Burshtein J","year":"2024","unstructured":"Burshtein J, Shah M, Zakria D, et al.. The efficacy and safety of bimekizumab for plaque psoriasis: an expert consensus panel. Dermatol Ther (Heidelb). 2024, 14:323-39. 10.1007\/s13555-024-01099-y","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/cjp.cjp_67_21","article-title":"Hidradenitis suppurativa: disease pathophysiology and sex hormones","volume":"64","author":"Chu CB","year":"2021","unstructured":"Chu CB, Yang CC, Tsai SJ. Hidradenitis suppurativa: disease pathophysiology and sex hormones. J Clin Med. 2021, 64:257-65. 10.4103\/cjp.cjp_67_21","journal-title":"J Clin Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich K","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al.. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021, 385:142-52. 10.1056\/NEJMoa2102383","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2637344","article-title":"Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years","volume":"37","author":"Gisondi P","year":"2026","unstructured":"Gisondi P, Elewski B, Pinter A, et al.. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years. J Dermatolog Treat. 2026, 37:2637344. 10.1080\/09546634.2026.2637344","journal-title":"J Dermatolog Treat"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","volume":"83","author":"Blauvelt A","year":"2020","unstructured":"Blauvelt A, Papp KA, Merola JF, et al.. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020, 83:1367-74. 10.1016\/j.jaad.2020.05.105","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver R","year":"2022","unstructured":"Oliver R, Krueger JG, Glatt S, et al.. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022, 186:652-63. 10.1111\/bjd.20827","journal-title":"Br J Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp KA","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, et al.. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018, 79:277-86.e10. 10.1016\/j.jaad.2018.03.037","journal-title":"J Am Acad Dermatol"},{"key":"ref37","unstructured":"Professional organisation submission. bimekizumab for treating moderate to severe chronic plaque psoriasis. (2021). Accessed: July 31, 2026: https:\/\/cdn.bad.org.uk\/uploads\/2022\/06\/06082603\/ID2692-Bimekizumab-professional-organisation-submission-template-BAD-...."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon KB","year":"2022","unstructured":"Gordon KB, Langley RG, Warren RB, et al.. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials. JAMA Dermatol. 2022, 158:735-44. 10.1001\/jamadermatol.2022.1185","journal-title":"JAMA Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber W","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al.. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012, 61:1693-700. 10.1136\/gutjnl-2011-301668","journal-title":"Gut"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492771-psoriasis-treatment-success-with-bimekizumab-two-hard-to-treat-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:42:41Z","timestamp":1786524161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492771-psoriasis-treatment-success-with-bimekizumab-two-hard-to-treat-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.114395","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}